Transforming Cancer Care with Oncosomes: Insight into Biogenesis, Functional Role, and Therapeutic Potential
Mohite P., Bogati R., Gorad A., Puri A., Singh S., Chittasupho C.
Narrative Review, published in Pharmaceutics (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Pharmaceutics (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41754949
- PMCID
- PMC12944223
- DOI
- 10.3390/pharmaceutics18020207
- Citations
- 1
Abstract (original English)
Oncosomes, a distinct subclass of extracellular vesicles released predominantly by tumor cells, have attracted increasing interest as potential carriers for targeted drug delivery in cancer research. Characterized by their large size (1-10 µm) and complex molecular cargo, including oncogenic proteins, nucleic acids, and lipids, oncosomes provide a biologically relevant platform for investigating tumor-associated communication and cargo transport. Preclinical studies suggest that oncosomes may enable tumor-associated delivery of therapeutic agents; however, evidence to date remains largely proof-of-concept and derived from in vitro and animal models. This review summarizes current knowledge on oncosome biogenesis and molecular composition; discusses their roles in cancer progression and metastasis; and critically evaluates existing methodologies for oncosome isolation, characterization, and cargo loading, including incubation, electroporation, sonication, freeze-thaw cycling, and transfection. Potential advantages such as cargo capacity and biological compatibility are discussed alongside key challenges, including vesicle heterogeneity, limited loading efficiency, large-scale manufacturing constraints, safety considerations, and regulatory uncertainty. Future perspectives focus on addressing these technical and translational barriers to support the systematic evaluation of engin
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.